Opus, Viatris say presbyopia drug succeeds in Phase 3
Opus Genetics and Viatris’ eye drug hit the primary endpoint in a Phase 3 study, putting them on track for an FDA filing by the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
